These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

501 related items for PubMed ID: 18491091

  • 1. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30.
    Perk LR, Stigter-van Walsum M, Visser GW, Kloet RW, Vosjan MJ, Leemans CR, Giaccone G, Albano R, Comoglio PM, van Dongen GA.
    Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1857-67. PubMed ID: 18491091
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging.
    Perk LR, Vosjan MJ, Visser GW, Budde M, Jurek P, Kiefer GE, van Dongen GA.
    Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):250-9. PubMed ID: 19763566
    [Abstract] [Full Text] [Related]

  • 5. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
    Perk LR, Visser GW, Vosjan MJ, Stigter-van Walsum M, Tijink BM, Leemans CR, van Dongen GA.
    J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605
    [Abstract] [Full Text] [Related]

  • 6. Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for 89Zr-immuno-PET.
    Vugts DJ, Klaver C, Sewing C, Poot AJ, Adamzek K, Huegli S, Mari C, Visser GWM, Valverde IE, Gasser G, Mindt TL, van Dongen GAMS.
    Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):286-295. PubMed ID: 27573793
    [Abstract] [Full Text] [Related]

  • 7. Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography.
    Perk LR, Visser OJ, Stigter-van Walsum M, Vosjan MJ, Visser GW, Zijlstra JM, Huijgens PC, van Dongen GA.
    Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1337-45. PubMed ID: 16832633
    [Abstract] [Full Text] [Related]

  • 8. Light-Induced Radiosynthesis of 89Zr-DFO-Azepin-Onartuzumab for Imaging the Hepatocyte Growth Factor Receptor.
    Klingler S, Fay R, Holland JP.
    J Nucl Med; 2020 Jul; 61(7):1072-1078. PubMed ID: 31924725
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab.
    Jagoda EM, Lang L, Bhadrasetty V, Histed S, Williams M, Kramer-Marek G, Mena E, Rosenblum L, Marik J, Tinianow JN, Merchant M, Szajek L, Paik C, Cecchi F, Raffensperger K, Jose-Dizon JM, Bottaro DP, Choyke P.
    J Nucl Med; 2012 Oct; 53(10):1592-600. PubMed ID: 22917884
    [Abstract] [Full Text] [Related]

  • 12. High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmunotherapy.
    Verel I, Visser GW, Vosjan MJ, Finn R, Boellaard R, van Dongen GA.
    Eur J Nucl Med Mol Imaging; 2004 Dec; 31(12):1645-52. PubMed ID: 15290121
    [Abstract] [Full Text] [Related]

  • 13. Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy.
    Vosjan MJ, Vercammen J, Kolkman JA, Stigter-van Walsum M, Revets H, van Dongen GA.
    Mol Cancer Ther; 2012 Apr; 11(4):1017-25. PubMed ID: 22319202
    [Abstract] [Full Text] [Related]

  • 14. ImmunoPET imaging of tissue factor expression in pancreatic cancer with 89Zr-Df-ALT-836.
    Hernandez R, England CG, Yang Y, Valdovinos HF, Liu B, Wong HC, Barnhart TE, Cai W.
    J Control Release; 2017 Oct 28; 264():160-168. PubMed ID: 28843831
    [Abstract] [Full Text] [Related]

  • 15. 89Zr-DFO-AMG102 Immuno-PET to Determine Local Hepatocyte Growth Factor Protein Levels in Tumors for Enhanced Patient Selection.
    Price EW, Carnazza KE, Carlin SD, Cho A, Edwards KJ, Sevak KK, Glaser JM, de Stanchina E, Janjigian YY, Lewis JS.
    J Nucl Med; 2017 Sep 28; 58(9):1386-1394. PubMed ID: 28280216
    [Abstract] [Full Text] [Related]

  • 16. Zr-89 Immuno-PET Targeting Ectopic ATP Synthase Enables In-Vivo Imaging of Tumor Angiogenesis.
    Park BN, Kim GH, Ko SA, Shin GH, Lee SJ, An YS, Yoon JK.
    Int J Mol Sci; 2019 Aug 13; 20(16):. PubMed ID: 31412537
    [Abstract] [Full Text] [Related]

  • 17. ImmunoPET imaging of renal cell carcinoma with (124)I- and (89)Zr-labeled anti-CAIX monoclonal antibody cG250 in mice.
    Stillebroer AB, Franssen GM, Mulders PF, Oyen WJ, van Dongen GA, Laverman P, Oosterwijk E, Boerman OC.
    Cancer Biother Radiopharm; 2013 Sep 13; 28(7):510-5. PubMed ID: 23697926
    [Abstract] [Full Text] [Related]

  • 18. ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody ⁸⁹Zr-RG7116.
    Terwisscha van Scheltinga AG, Lub-de Hooge MN, Abiraj K, Schröder CP, Pot L, Bossenmaier B, Thomas M, Hölzlwimmer G, Friess T, Kosterink JG, de Vries EG.
    MAbs; 2014 Sep 13; 6(4):1051-8. PubMed ID: 24870719
    [Abstract] [Full Text] [Related]

  • 19. Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody.
    Christensen C, Kristensen LK, Alfsen MZ, Nielsen CH, Kjaer A.
    Eur J Nucl Med Mol Imaging; 2020 May 13; 47(5):1302-1313. PubMed ID: 31883023
    [Abstract] [Full Text] [Related]

  • 20. Probody Therapeutic Design of 89Zr-CX-072 Promotes Accumulation in PD-L1-Expressing Tumors Compared to Normal Murine Lymphoid Tissue.
    Giesen D, Broer LN, Lub-de Hooge MN, Popova I, Howng B, Nguyen M, Vasiljeva O, de Vries EGE, Pool M.
    Clin Cancer Res; 2020 Aug 01; 26(15):3999-4009. PubMed ID: 31953313
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.